Form 4: Pfizer Director Echevarria Reports Acquisition of Phantom Stock Units

Director Joseph Echevarria reported the acquisition of phantom stock units representing deferred director's compensation in a recent SEC filing.

Summary

• On March 28, 2024, Joseph Echevarria, a director of Pfizer Inc., acquired 1,666.667 phantom stock units.
• These units represent deferred director's compensation, including dividend equivalents.
• The units will be settled in cash or common stock at the director's election following retirement from the Board of Directors.
• Following the transaction, Echevarria directly owns 105,119.972 shares of common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects standard director compensation practices and aligns director interests with the company's long-term performance.

Positives

• The acquisition of phantom stock units aligns the director's interests with the long-term performance of the company.
• Deferred compensation plans can be tax-efficient for both the company and the director.

Future Outlook

The phantom stock units will be settled in cash or common stock at the director's election following retirement from the Board of Directors.

Industry Context

Director compensation packages often include phantom stock units to align executive interests with shareholder value and encourage long-term commitment.

Comparison to Industry Standards

• Pfizer's director compensation practices, including the use of phantom stock units, are common among large publicly traded companies.
• Companies like Johnson & Johnson and Merck also utilize similar deferred compensation mechanisms for their board members.

Stakeholder Impact

• The acquisition of phantom stock units by a director can positively influence shareholder confidence by aligning management's interests with shareholder value.

Key Dates